skip to main content
Idioma:

Moderate‐to‐severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real‐world experience

Stingeni, L. ; Bianchi, L. ; Antonelli, E. ; Caroppo, E.S. ; Ferrucci, S.M. ; Ortoncelli, M. ; Fabbrocini, G. ; Nettis, E. ; Schena, D. ; Napolitano, M. ; Gola, M. ; Bonzano, L. ; Rossi, M. ; Belloni Fortina, A. ; Balato, A. ; Peris, K. ; Foti, C. ; Guarneri, F. ; Romanelli, M. ; Patruno, C. ; Savoia, P. ; Fargnoli, M.C. ; Russo, F. ; Errichetti, E. ; Bianchelli, T. ; Bianchi, L. ; Pellacani, G. ; Feliciani, C. ; Offidani, A. ; Corazza, M. ; Micali, G. ; Milanesi, N. ; Malara, G. ; Chiricozzi, A. ; Tramontana, M. ; Hansel, K. ; Bini, Vittorio ; Buligan, Cinzia ; Caroppo, Francesca ; Dal Bello, Giacomo ; Dastoli, Stefano ; Di Brizzi, Eugenia Veronica ; De Felici Del Giudice, Maria Beatrice ; Diluvio, Laura ; Esposito, Maria ; Gelmetti, Alessandra ; Giacchetti, Alfredo ; Grieco, Teresa ; Iannone, Michela ; Macchia, Luigi ; Marietti, Rossella ; Musumeci, Maria Letizia ; Peccerillo, Francesca ; Pluchino, Francesco ; Radi, Giulia ; Ribero, Simone ; Romita, Paolo ; Tavecchio, Simona ; Tronconi, Greta ; Veronese, Federica

Journal of the European Academy of Dermatology and Venereology, 2022-08, Vol.36 (8), p.1292-1299 [Periódico revisado por pares]

England

Texto completo disponível

Citações Citado por
  • Título:
    Moderate‐to‐severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real‐world experience
  • Autor: Stingeni, L. ; Bianchi, L. ; Antonelli, E. ; Caroppo, E.S. ; Ferrucci, S.M. ; Ortoncelli, M. ; Fabbrocini, G. ; Nettis, E. ; Schena, D. ; Napolitano, M. ; Gola, M. ; Bonzano, L. ; Rossi, M. ; Belloni Fortina, A. ; Balato, A. ; Peris, K. ; Foti, C. ; Guarneri, F. ; Romanelli, M. ; Patruno, C. ; Savoia, P. ; Fargnoli, M.C. ; Russo, F. ; Errichetti, E. ; Bianchelli, T. ; Bianchi, L. ; Pellacani, G. ; Feliciani, C. ; Offidani, A. ; Corazza, M. ; Micali, G. ; Milanesi, N. ; Malara, G. ; Chiricozzi, A. ; Tramontana, M. ; Hansel, K. ; Bini, Vittorio ; Buligan, Cinzia ; Caroppo, Francesca ; Dal Bello, Giacomo ; Dastoli, Stefano ; Di Brizzi, Eugenia Veronica ; De Felici Del Giudice, Maria Beatrice ; Diluvio, Laura ; Esposito, Maria ; Gelmetti, Alessandra ; Giacchetti, Alfredo ; Grieco, Teresa ; Iannone, Michela ; Macchia, Luigi ; Marietti, Rossella ; Musumeci, Maria Letizia ; Peccerillo, Francesca ; Pluchino, Francesco ; Radi, Giulia ; Ribero, Simone ; Romita, Paolo ; Tavecchio, Simona ; Tronconi, Greta ; Veronese, Federica
  • É parte de: Journal of the European Academy of Dermatology and Venereology, 2022-08, Vol.36 (8), p.1292-1299
  • Notas: Funding sources
    None.
    The patient and their parents in this manuscript have given written informed consent to publication of their case details.
    Conflict of Interest
    L. S. has been principal investigator in clinical trials sponsored by and/or and has received personal fees for participation in advisory board from Abbvie, LeoPharma, Novartis and Sanofi, outside the submitted work; G.F. has been principal investigator in clinical trials sponsored by and/or and has received personal fees from Abbvie, Abiogen, Almirall, Celgene, Eli‐Lilly, Leo Pharma, Novartis, Sanofi and UCB, outside the submitted work; E.N. has been Advisory board member for Sanofi, outside the submitted work; M.N. acted as speaker, consultant and advisory board member for Sanofi, Abbvie, Leo Pharma, Novartis and Lilly, outside the submitted work; F.G. received support for attending meetings and/or travel from Sanofi, outside the submitted work; M.C.F. received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and for participation on a data safety monitoring board or advisory board from Sanofi, Lilly, Abbvie, Galderma and Pfizer, outside the submitted work; A.O. has been principal investigator in clinical trials sponsored by and/or and has received personal fees from Abbvie, LeoPharma and Sanofi, outside the submitted work; A.C. received consulting fees from Abbvie, Almirall, Biogen, Incyte, Leo Pharma, Lilly, Janssen, Novartis, Pfizer and Sanofi and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Almirall, LeoPharma, Lilly, Janssen, Novartis and Sanofi, outside the submitted work; K.H. reports personal fees from Abbvie and Novartis, outside the submitted work; L.B., E.A., E.S.C., S.M.F, M.O., D.S., M.G., L.B., M.R., A.B.F., A.B., K.P., C.F., M.R., C.P., P.S., F.R., E.E., T.B., L.B., G.P., C.F., M.C., G.M., N.M., G.M. and M.T. report no conflicts of interest.
    DADA study group are present in Appendix
    ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: Background Moderate‐to‐severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side‐effects. Dupilumab was recently approved for treatment of adolescent AD. Objectives A multicentre, prospective, real‐world study on the effectiveness and safety of dupilumab in adolescents (aged from ≥12 to <18 years) with moderate‐to‐severe AD was conducted. The main AD clinical phenotypes were also examined. Methods Data of adolescents with moderate‐to‐severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. Results One hundred and thirty‐nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait‐like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS‐CoV‐2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty‐eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. Conclusions Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID‐19 pandemic era.
  • Editor: England
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.